Skip to main content
Top
Published in: Journal of Orthopaedic Surgery and Research 1/2015

Open Access 01-12-2015 | Research article

Positive side effects of Ca antagonists for osteoarthritic joints—results of an in vivo pilot study

Authors: Kiriakos Daniilidis, Philipp Georges, Carsten O Tibesku, Peter Prehm

Published in: Journal of Orthopaedic Surgery and Research | Issue 1/2015

Login to get access

Abstract

Background

We have shown previously that some calcium antagonists inhibit hyaluronan export, loss of proteoglycans, and degradation of collagen from osteoarthritic cartilage. Clinically approved calcium antagonists normally are prescribed for cardiac arrhythmia. In the present study, we compared the effect of these drugs on osteoarthritic patients which had received no medication and patients which were also diagnosed for cardiac arrhythmias and were treated with calcium antagonists. The effects and the side effects of the used drugs were analyzed.

Method

We used the Lequesne questionnaire to examine patients with osteoarthritis (212 patients, control group receiving no calcium antagonists) and patients with cardiac arrhythmia and osteoarthritis (188 patients treated with various calcium antagonists). The answers of the questionnaires were transformed into the Lequesne scoring system quantifying the severity of the disease. The Lequesne score is a standardized questionnaire focused on osteoarthritis. It is a 24-scale questionary in which low scores indicate low functional activity.

Results

The data showed that the mean score of the control group (6.2) was higher than the treated group (5.2), the drugs differed in their efficiency. Verapamil had a slightly worse score and Azupamil, Escor, Felodipine, and Nifedipine showed no alteration. Adalat, Amlodipine, Carmen, Nitrendipin, and Norvasc lead to an improvement.

Conclusion

These results suggest that inhibition of hyaluronan export may have a beneficial effect on human osteoarthritis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778–99.PubMedCrossRef Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778–99.PubMedCrossRef
2.
go back to reference Le Graverand-Gastineau MP. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets. 2010;11(5):528–35.PubMedCrossRef Le Graverand-Gastineau MP. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets. 2010;11(5):528–35.PubMedCrossRef
3.
go back to reference Greenwald RA. Thirty-six years in the clinic without an MMP inhibitor. What hath collagenase wrought? Ann N Y Acad Sci. 1999;878:413–9.PubMedCrossRef Greenwald RA. Thirty-six years in the clinic without an MMP inhibitor. What hath collagenase wrought? Ann N Y Acad Sci. 1999;878:413–9.PubMedCrossRef
4.
go back to reference Elliott S, Cawston T. The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders. Drugs Aging. 2001;18:87–99.PubMedCrossRef Elliott S, Cawston T. The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders. Drugs Aging. 2001;18:87–99.PubMedCrossRef
5.
go back to reference Kozaci LD, Buttle DJ, Hollander AP. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum. 1997;40:164–74.PubMedCrossRef Kozaci LD, Buttle DJ, Hollander AP. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum. 1997;40:164–74.PubMedCrossRef
6.
go back to reference Billinghurst RC, Wu W, Ionescu M, Reiner A, Dahlberg L, Chen J, et al. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum. 2000;43:664–72.PubMedCrossRef Billinghurst RC, Wu W, Ionescu M, Reiner A, Dahlberg L, Chen J, et al. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum. 2000;43:664–72.PubMedCrossRef
7.
go back to reference Prehm P, Schumacher U. Inhibition of hyaluronan export from human fibroblasts by inhibitors of multidrug resistance transporters. Biochem Pharmacol. 2004;68:1401–10.PubMedCrossRef Prehm P, Schumacher U. Inhibition of hyaluronan export from human fibroblasts by inhibitors of multidrug resistance transporters. Biochem Pharmacol. 2004;68:1401–10.PubMedCrossRef
8.
go back to reference Prehm P. Inhibitors of hyaluronan export prevent proteoglycan loss from osteoarthritic cartilage. J Rheumatol. 2005;32:690–6.PubMed Prehm P. Inhibitors of hyaluronan export prevent proteoglycan loss from osteoarthritic cartilage. J Rheumatol. 2005;32:690–6.PubMed
9.
go back to reference Schulz T, Schumacher U, Prehm P. Hyaluronan export by the ABC-transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007;282:20999–1004.PubMedCrossRef Schulz T, Schumacher U, Prehm P. Hyaluronan export by the ABC-transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007;282:20999–1004.PubMedCrossRef
10.
11.
go back to reference Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation—value in comparison with other assessment tests. Scand J Rheumatol Suppl. 1987;65:85–9.PubMedCrossRef Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation—value in comparison with other assessment tests. Scand J Rheumatol Suppl. 1987;65:85–9.PubMedCrossRef
12.
go back to reference Hagenfeld D, Borkenhagen B, Schulz T, Schillers H, Schumacher U, Prehm P. Hyaluronan export through plasma membranes depends on concurrent K(+) efflux by K(ir) channels. PLoS One. 2012;7:e39096.PubMedCentralPubMedCrossRef Hagenfeld D, Borkenhagen B, Schulz T, Schillers H, Schumacher U, Prehm P. Hyaluronan export through plasma membranes depends on concurrent K(+) efflux by K(ir) channels. PLoS One. 2012;7:e39096.PubMedCentralPubMedCrossRef
13.
go back to reference Eichhorn B, Dobrev D. Vascular large conductance calcium-activated potassium channels: functional role and therapeutic potential. Naunyn Schmiedebergs Arch Pharmacol. 2007;376:145–55.PubMedCrossRef Eichhorn B, Dobrev D. Vascular large conductance calcium-activated potassium channels: functional role and therapeutic potential. Naunyn Schmiedebergs Arch Pharmacol. 2007;376:145–55.PubMedCrossRef
Metadata
Title
Positive side effects of Ca antagonists for osteoarthritic joints—results of an in vivo pilot study
Authors
Kiriakos Daniilidis
Philipp Georges
Carsten O Tibesku
Peter Prehm
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Orthopaedic Surgery and Research / Issue 1/2015
Electronic ISSN: 1749-799X
DOI
https://doi.org/10.1186/s13018-014-0138-8

Other articles of this Issue 1/2015

Journal of Orthopaedic Surgery and Research 1/2015 Go to the issue